Author pages are created from data sourced from our academic publisher partnerships and public sources.
- Publications
- Influence
Share This Author
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
- Daniel W. Lee, J. Kochenderfer, C. Mackall
- Medicine, BiologyThe Lancet
- 7 February 2015
Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes
- R. Morgan, M. Dudley, S. Rosenberg
- Biology, MedicineScience
- 6 October 2006
TLDR
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
- M. Dudley, J. Wunderlich, S. Rosenberg
- Medicine, BiologyScience
- 19 September 2002
TLDR
Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.
- R. Morgan, J. Yang, M. Kitano, M. Dudley, C. Laurencot, S. Rosenberg
- Biology, MedicineMolecular therapy : the journal of the American…
- 1 April 2010
TLDR
Cancer immunotherapy: moving beyond current vaccines
- S. Rosenberg, J. Yang, N. Restifo
- Medicine, BiologyNature Medicine
- 1 September 2004
TLDR
Adoptive cell transfer as personalized immunotherapy for human cancer
- S. Rosenberg, N. Restifo
- BiologyScience
- 3 April 2015
TLDR
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.
- J. Yang, Leah R. Haworth, S. Rosenberg
- MedicineThe New England journal of medicine
- 31 July 2003
TLDR
Adoptive cell transfer: a clinical path to effective cancer immunotherapy
- S. Rosenberg, N. Restifo, J. Yang, R. Morgan, M. Dudley
- Medicine, BiologyNature Reviews Cancer
- 1 April 2008
TLDR
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.
- L. Johnson, R. Morgan, S. Rosenberg
- Biology, MedicineBlood
- 16 July 2009
TLDR
A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.
- S. Rosenberg, M. Lotze, J. Rubin
- MedicineThe New England journal of medicine
- 9 April 1987
TLDR
...
...